ICLR · Icon PLC
$168.91
-4.57 (-2.63%)
At close · Aug 25
Market Cap
$13.29B
Shares
77.15M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$168.91
Open$172.69
Day$168.01–173.00
52W close$80.08–202.92
Avg vol 30d741K
Short int2.2M · 2.9% float · 3.5d
Short vol65%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
+2%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+53%
trailing
YTD return
−7%
this year
Relative strength
+41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $165 › 200d $147 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +89 funds added
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Falling
2.88% of float · ▼ -0.1% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
428 holders — near 3-yr low, contrarian setup
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
−67%
Y/Y
Free cash flow
$862.0M
Valuation
P/E 265
rich
Buyback
$750.0M
remaining
Balance sheet
$2.2B
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Revenue
· full year 2026
$7.85B – $8.15B
Adjusted diluted earnings per share
· full year 2026
Non-GAAP
$10.00 – $11.00
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Full year revenue
· full year
$8.05B – $8.1B
Full year adjusted earnings per share
· full year
$13.00 – $13.20
Guided vs delivered
· last 3 settled
Revenue
full year 2023
guided $8.07B – $8.21B
$8.05B
Miss −1.0%
Revenue
full-year 2022
guided $7.69B – $7.81B
$7.74B
In line
Earnings per share
full-year 2022
guided $11.65 – $11.85
$6.13
Miss −47.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $165 › 200d $147 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +89 funds added
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Falling
2.88% of float · ▼ -0.1% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
428 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $80
Now $169 · 72%
Range high $203
vs 200-day avg +15%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICLR
this stock
Icon PLC
|
$13.29B | -7.3% | +19.8% | 265.0 | 2.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$232.47B | +8.4% | +14.5% | 33.8 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.82B | -5.7% | +8.5% | 38.3 | 1.2% |
|
NTRA
Natera, Inc.
|
$47.12B | +47.0% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.88B | -18.7% | +10.4% | 39.1 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICLR | +1.1% | -6.3% | +53.3% | +3.3% | -7.3% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | +1.3% | -9.7% | +41.5% | +0.7% | -19.6% |
Capital returns
Buyback programs
· 4 active
· as of Jun 30, 2026
Authorized (total)
$2.50B
Spent (derived)
$1.75B
Remaining
$750.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1060955
CUSIP
G4705A100
13F (30d)
381 filings
353 filers
Visit website
Investor relations